Minot Light Capital Partners, an investment management company, released its Q3 2025 investment letter. A copy of the letter can be downloaded here. In the quarter, Minot Light generated solid returns for limited partners, with a net of 7.6%. However, on a net basis, the performance underperformed the benchmarks, particularly the micro-cap benchmark’s 17.1% return. In addition, please check the fund’s top five holdings to know its best picks in 2025.
In its third-quarter 2025 investor letter, Minot Light Capital Partners highlighted stocks such as ClearPoint Neuro, Inc. (NASDAQ:CLPT). ClearPoint Neuro, Inc. (NASDAQ:CLPT) is a medical device company that focuses on the development of platforms for performing minimally invasive surgical procedures. The one-month return for ClearPoint Neuro, Inc. (NASDAQ:CLPT) was -1.58%, and its shares lost 8.50% over the last 52 weeks. On December 23, 2025, ClearPoint Neuro, Inc. (NASDAQ:CLPT) stock closed at $14.37 per share, with a market capitalization of $427.483 million.
Minot Light Capital Partners stated the following regarding ClearPoint Neuro, Inc. (NASDAQ:CLPT) in its third quarter 2025 investor letter:
“ClearPoint Neuro, Inc. (NASDAQ:CLPT): ClearPoint is a company that provides both hardware and consumables to allow for the precise delivery of drugs to the brain and spine, with a particular focus on cell and gene therapies. The company offers both navigation systems (hardware) and a variety of accessories (consumables). Because its technologies are critical to various cell and gene therapies, they are initially used in clinical trials and eventually become an integral component to the delivery of these drugs when and if they are approved by FDA. This creates a long-term growth opportunity, characterized by high switching costs on a variety of recurring revenue streams. In many ways, ClearPoint is emblematic of many of our current holdings in the healthcare space, which are characterized by strong business models, high growth potential, and substantial embedded optionality, but have fallen very much out of favor relative to high-growth stocks in other sectors during the current healthcare sector downturn.
In the case of ClearPoint, some of that optionality began to pay off this quarter because uniQure (QURE), one of ClearPoint’s partners, reported excellent clinical data for its Huntington’s Disease drug, which dramatically increased the odds of its eventual approval and reimbursement. If approved, this drug will have a profound impact on patients and provide a meaningful revenue stream to ClearPoint. It also serves as a proof point and source of optimism for other neurological cell and gene therapies that have integrated ClearPoint protocols into their therapies. We owned ClearPoint going into the uniQure news and continue to hold a position, as it remains a strong platform going forward with large growth prospects. Though no longer optically cheap, the valuation is reasonable if the company’s pipeline continues to come to fruition and its installed base of hardware continues to expand. In addition, the market cap has now moved from well below $500M to over $800M, which brings shares of ClearPoint onto the radar of larger institutional small-cap funds, of which few seemed to own any stock prior to this recent move. This fits the paradigm of our core holdings that are ejecting out of micro-cap into what we would call the small-cap sweet spot.”
ClearPoint Neuro, Inc. (NASDAQ:CLPT) is not on our list of 30 Most Popular Stocks Among Hedge Funds. According to our database, 10 hedge fund portfolios held ClearPoint Neuro, Inc. (NASDAQ:CLPT) at the end of the third quarter, the same as in the previous quarter. While we acknowledge the risk and potential of ClearPoint Neuro, Inc. (NASDAQ:CLPT) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ClearPoint Neuro, Inc. (NASDAQ:CLPT) and that has 10,000% upside potential, check out our report about this cheapest AI stock.
In another article, we covered ClearPoint Neuro, Inc. (NASDAQ:CLPT) and shared Deep Sail Capital’s views on the company. In addition, please check out our hedge fund investor letters Q3 2025 page for more investor letters from hedge funds and other leading investors.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None. This article is originally published at Insider Monkey.
